BEIJING--(BUSINESS WIRE)--Regulatory News:
The National Health and Family Planning Commission (NHFPC) of the People’s Republic of China announced today that Elekta (STO:EKTAB) has won a major tender for seven Leksell Gamma Knifeâ Perfexion™ units, making it the largest single order of Leksell Gamma Knife systems. The deal has a total value of around USD 25 million.
Elekta was awarded the tender through a central procurement project organized by the NHFPC. Purchasing the Perfexion units is part of the Chinese government’s continuous investment in health care.
With its large unmet need for cancer care and neurological disorders, China continues to grow and is Elekta’s second largest market. Elekta has been present in China since 1982 and is today the market leader with approximately 48 percent of the radiation therapy market share.
# # #
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11:00 CET on September 10, 2013.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com